COVID-19 Information

PolyPeptide Group – response to the COVID-19 outbreak

April 1st , 2021

 

Dear valued customer,

While the COVID-19 pandemic still increases in some parts of the world, the PolyPeptide Group continues to closely monitor the situation and its global impact.

Our priorities remain to protect the health and safety of all our employees. In these incredibly challenging times, Teams all across our company are going above and beyond to meet our promises to customers and save patient lives.

We are committed to stay resilient and agile to keep employees safe and our six sites running as fully as possible. We will continue to:

  • Stagger schedules to support social distancing.
  • Offer work-from-home options.
  • Offer non-overlapping team shifts where possible and extend hours of operation to support social distancing
  • Provide masks and appropriate PPE.
  • Rigorously clean work areas regularly.
  • Standardize our primary communication tools for remote meetings internally and with clients
  • Restrict access to our facilities (from outsiders) to business-critical needs
  • Organize virtual audits
  • Use tools for Project Management Teams to allow for digital tracking of Projects.
  • Closely follow up with our suppliers

Feel free to reach out to us for more information Contact us

Thank you for your trust and understanding. Wishing you and your family good health.

Kind regards,

Jane Salik, CEO

 

The PolyPeptide Group’s engagement in peptide-based therapies and vaccines to combat COVID-19

As a Global Leader in Peptide Manufacturing and Development, the PolyPeptide Group has been actively engaged on projects with clients who are developing peptide-based therapies and vaccines to combat COVID-19. The Group has been active in supporting multiple COVID-19 projects, and partners with a variety of global pharmaceutical, biotech and research institutions to support their urgent research in the fight against disease and the serious symptoms caused by COVID-19. In addition to our involvement in the manufacture of the Matrix M adjuvant components for the Novavax COVID-19 vaccine currently in clinical trials, The PolyPeptide Group is working on several projects that can treat COVID-19 symptoms, especially Acute Respiratory Distress Syndrome (ARDS) a common effect of the virus.